JP2025114622A5 - - Google Patents
Info
- Publication number
- JP2025114622A5 JP2025114622A5 JP2025072400A JP2025072400A JP2025114622A5 JP 2025114622 A5 JP2025114622 A5 JP 2025114622A5 JP 2025072400 A JP2025072400 A JP 2025072400A JP 2025072400 A JP2025072400 A JP 2025072400A JP 2025114622 A5 JP2025114622 A5 JP 2025114622A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- region
- terminus
- hepatitis
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160149866 | 2016-11-10 | ||
| KR10-2016-0149866 | 2016-11-10 | ||
| PCT/KR2017/012726 WO2018088838A1 (en) | 2016-11-10 | 2017-11-10 | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| JP2019524255A JP7328891B2 (ja) | 2016-11-10 | 2017-11-10 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
| JP2022156834A JP2023002571A (ja) | 2016-11-10 | 2022-09-29 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022156834A Division JP2023002571A (ja) | 2016-11-10 | 2022-09-29 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025114622A JP2025114622A (ja) | 2025-08-05 |
| JP2025114622A5 true JP2025114622A5 (https=) | 2025-10-14 |
Family
ID=62110477
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524255A Active JP7328891B2 (ja) | 2016-11-10 | 2017-11-10 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
| JP2022156834A Pending JP2023002571A (ja) | 2016-11-10 | 2022-09-29 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
| JP2025072400A Pending JP2025114622A (ja) | 2016-11-10 | 2025-04-24 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524255A Active JP7328891B2 (ja) | 2016-11-10 | 2017-11-10 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
| JP2022156834A Pending JP2023002571A (ja) | 2016-11-10 | 2022-09-29 | 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11179440B2 (https=) |
| EP (1) | EP3568149B1 (https=) |
| JP (3) | JP7328891B2 (https=) |
| KR (1) | KR102692516B1 (https=) |
| CN (1) | CN110121355B (https=) |
| AU (2) | AU2017358289C1 (https=) |
| BR (1) | BR112019009581A2 (https=) |
| CA (1) | CA3042512A1 (https=) |
| ES (1) | ES3023833T3 (https=) |
| HU (1) | HUE071618T2 (https=) |
| MX (1) | MX2019005380A (https=) |
| NZ (2) | NZ794313A (https=) |
| PL (1) | PL3568149T3 (https=) |
| WO (1) | WO2018088838A1 (https=) |
| ZA (1) | ZA201903306B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US11560416B2 (en) | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
| WO2019243557A1 (en) | 2018-06-21 | 2019-12-26 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
| EP3935075A4 (en) | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| US20230265152A1 (en) * | 2020-07-02 | 2023-08-24 | Sanofi | Glp-1r agonist / fgf21 fusion proteins |
| WO2023284822A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| KR20250039300A (ko) * | 2023-09-11 | 2025-03-20 | 서울대학교병원 | 안지오포이에틴-1 융합 단백질 및 이의 용도 |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| WO1990002175A1 (en) | 1988-08-16 | 1990-03-08 | Novo Nordisk A/S | A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors |
| US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| JP2007531715A (ja) | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| JP2006094727A (ja) * | 2004-09-28 | 2006-04-13 | Masaki Kamakura | 細胞増殖促進作用及び器官再生促進作用を有すポリペプチドをコードする遺伝子 |
| HUE035243T2 (hu) | 2007-02-23 | 2018-05-02 | Sk Chemicals Co Ltd | Eljárás VIII. faktor és származékainak elõállítására és tisztítására |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| US8034770B2 (en) * | 2008-06-04 | 2011-10-11 | Amgen Inc. | FGF21 polypeptides comprising two or more mutations |
| CN101732715B (zh) * | 2008-11-07 | 2012-02-15 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | LSECtin及其融合蛋白在制备抑制癌细胞向肝转移药物中的应用 |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| WO2010129503A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| JP2012529463A (ja) | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー／エス | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ |
| CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| ES2543634T3 (es) | 2010-01-22 | 2015-08-20 | Novo Nordisk A/S | Proceso para preparación de FGF-21 con grado de O-glicosilación bajo |
| CN103415300B (zh) | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| CN102370686B (zh) * | 2010-08-26 | 2013-09-18 | 上海中医药大学附属曙光医院 | 治疗慢性肝病的药物组合物及其应用 |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| MX2014002260A (es) | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| CN102558358A (zh) * | 2011-12-30 | 2012-07-11 | 张海涛 | 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用 |
| WO2013131091A1 (en) | 2012-03-02 | 2013-09-06 | New York University | Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders |
| TWI513705B (zh) * | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CN103860565B (zh) * | 2012-12-10 | 2017-05-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种治疗肝纤维化的药物组合物 |
| US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
| JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| WO2016048995A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf19 truncations and mutants and uses thereof |
| CN114805532A (zh) * | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| CN105288592A (zh) | 2015-11-02 | 2016-02-03 | 哈尔滨博翱生物医药技术开发有限公司 | 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用 |
| WO2018166461A1 (en) * | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| US11560416B2 (en) | 2017-04-21 | 2023-01-24 | Yuhan Corporation | Method for producing dual function proteins and its derivatives |
-
2017
- 2017-11-10 MX MX2019005380A patent/MX2019005380A/es unknown
- 2017-11-10 WO PCT/KR2017/012726 patent/WO2018088838A1/en not_active Ceased
- 2017-11-10 JP JP2019524255A patent/JP7328891B2/ja active Active
- 2017-11-10 PL PL17870009.2T patent/PL3568149T3/pl unknown
- 2017-11-10 US US16/348,249 patent/US11179440B2/en active Active
- 2017-11-10 NZ NZ794313A patent/NZ794313A/en unknown
- 2017-11-10 AU AU2017358289A patent/AU2017358289C1/en active Active
- 2017-11-10 HU HUE17870009A patent/HUE071618T2/hu unknown
- 2017-11-10 NZ NZ794312A patent/NZ794312A/en unknown
- 2017-11-10 BR BR112019009581A patent/BR112019009581A2/pt unknown
- 2017-11-10 EP EP17870009.2A patent/EP3568149B1/en active Active
- 2017-11-10 ES ES17870009T patent/ES3023833T3/es active Active
- 2017-11-10 KR KR1020170149338A patent/KR102692516B1/ko active Active
- 2017-11-10 CA CA3042512A patent/CA3042512A1/en active Pending
- 2017-11-10 CN CN201780069241.3A patent/CN110121355B/zh active Active
-
2019
- 2019-05-24 ZA ZA2019/03306A patent/ZA201903306B/en unknown
-
2022
- 2022-09-29 JP JP2022156834A patent/JP2023002571A/ja active Pending
-
2025
- 2025-03-12 AU AU2025201790A patent/AU2025201790A1/en active Pending
- 2025-04-24 JP JP2025072400A patent/JP2025114622A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025114622A5 (https=) | ||
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| JP2024138397A5 (https=) | ||
| JP2023525033A5 (https=) | ||
| US20140005361A1 (en) | FC-Interferon-Beta Fusion Proteins | |
| JP2004528014A5 (https=) | ||
| CN108136276B (zh) | 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物 | |
| JP2007505643A5 (https=) | ||
| JP2023504914A5 (https=) | ||
| AU2004247042A1 (en) | Fusion proteins | |
| RU2007132188A (ru) | Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo | |
| CN104039831A (zh) | 免疫球蛋白fc变体 | |
| JPH0696599B2 (ja) | 化学修飾リンホカインおよびその製造法 | |
| JP2008507298A5 (https=) | ||
| JP2020533020A5 (https=) | ||
| JP7752664B2 (ja) | 新規な中間体製造による持続型薬物結合体の製造方法 | |
| EP2817326A1 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| WO2003062370B1 (en) | Multimeric proteins and methods of making and using same | |
| US9394546B2 (en) | Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same | |
| JP2019500390A (ja) | 持続型ヒト成長ホルモン結合体の新規液状製剤 | |
| JP2024501770A5 (https=) | ||
| NZ752661B2 (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins | |
| NZ752661A (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| WO2026082073A1 (zh) | 一种嵌合利钠肽或其变体及其应用 |